The program will make use of extensive patient cohorts and the findings from DOSIS to optimize care for cardiomyopathy patients. The cost-effectiveness of current diagnostics and clinical care from both patient and societal perspective will be quantified. Furthermore, the aim is to translate the findings that metabolic alterations are central to cardiomyopathies, by initiating at least one clinical trial based on treatment(s) that reduce metabolic stress. The Double Dose program will establish serum, tissue and iPSC-CMs biobanks from a large set of cardiomyopathy patients. The consortium will provide mechanistic pre-clinical and clinical insight into the link between metabolic stress and cardiomyopathy pathophysiology, and translate these findings to optimize diagnosis and care of cardiomyopathy patients.
For more information: https://dcvalliance.nl/our-consortia/double-dose
